Literature DB >> 15014664

Interventions for Weight Gain in Adults Treated With Novel Antipsychotics.

Ralph Aquila1, Marianne Emanuel.   

Abstract

BACKGROUND: Weight gain is a significant side effect associated with typical and atypical antipsychotic agents. It has the potential to add to the increased morbidity and mortality associated with schizophrenia and schizoaffective disorder. Because the newer antipsychotic medications have proved to be superior to traditional agents in controlling the positive and negative symptoms of schizophrenia, it is additionally critical to address the relationship of these newer agents to weight gain.
METHOD: Prior to the availability of novel antipsychotic medication, we looked at a group of 17 residents, of whom 71% had significant weight gain on treatment with traditional antipsychotic medications between 1991 and 1994. This prompted our interest in weight gain, especially after the introduction of novel antipsychotic medications, and our decision to look closely at their diets and help them make changes that would minimize their weight gain. We monitored the effect of a comprehensive primary intervention strategy on controlling obesity in a retrospective study of 32 patients with DSM-IV schizophrenia or schizoaffective disorders. All patients were residents in an adult care facility for formerly homeless persons with serious mental illness. Intervention consisted of complete medical and psychiatric care; switch to a patient-optimal atypical drug; low-calorie, monitored diet; nutritional education; and supportive care.
RESULTS: There was no significant change in mean body weight at 12 and 18 months after initiation of intervention. Weight gain was observed in only 30% of study patients after the intervention as opposed to 71% at the start of the study. In general, as the negative symptoms of schizophrenia improved, patients were found to become more receptive to education and to become proactive in their health care. The lack of weight gain was consistently seen with all 3 agents tested-clozapine, olanzapine, and risperidone.
CONCLUSION: A patient's diet appears to be a better predictor of weight gain than the choice of novel antipsychotic medication. Clinicians might prescribe nutritional and lifestyle changes alongside medication with weight gain potential.

Entities:  

Year:  2000        PMID: 15014664      PMCID: PMC181105          DOI: 10.4088/pcc.v02n0106

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  8 in total

1.  Clozapine-induced weight gain: prevalence and clinical relevance.

Authors:  R Leadbetter; M Shutty; D Pavalonis; V Vieweg; P Higgins; M Downs
Journal:  Am J Psychiatry       Date:  1992-01       Impact factor: 18.112

2.  Excess mortality of schizophrenia. A meta-analysis.

Authors:  S Brown
Journal:  Br J Psychiatry       Date:  1997-12       Impact factor: 9.319

3.  Clozapine and weight gain.

Authors:  D S Umbricht; S Pollack; J M Kane
Journal:  J Clin Psychiatry       Date:  1994-09       Impact factor: 4.384

Review 4.  Induction of obesity by psychotropic drugs.

Authors:  J G Bernstein
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

5.  Weight gain among schizophrenic patients treated with clozapine.

Authors:  J S Lamberti; T Bellnier; S B Schwarzkopf
Journal:  Am J Psychiatry       Date:  1992-05       Impact factor: 18.112

6.  Health and mental health problems of homeless men and women in Baltimore.

Authors:  W R Breakey; P J Fischer; M Kramer; G Nestadt; A J Romanoski; A Ross; R M Royall; O C Stine
Journal:  JAMA       Date:  1989-09-08       Impact factor: 56.272

7.  Compliance with antipsychotic drug treatment: influence of side effects.

Authors:  W W Fleischhacker; U Meise; V Günther; M Kurz
Journal:  Acta Psychiatr Scand Suppl       Date:  1994

8.  Differential effect of clozapine on weight: a controlled study.

Authors:  J R Bustillo; R W Buchanan; D Irish; A Breier
Journal:  Am J Psychiatry       Date:  1996-06       Impact factor: 18.112

  8 in total
  10 in total

1.  Dramatic weight loss associated with commencing clozapine.

Authors:  John Lally; Colm McDonald
Journal:  BMJ Case Rep       Date:  2011-11-08

2.  Perceptions and dietary intake of self-described healthy and unhealthy eaters with severe mental illness.

Authors:  Nancy E Carson; Christine E Blake; Ruth Saunders
Journal:  Community Ment Health J       Date:  2014-12-23

Review 3.  Lifestyle interventions for adults with serious mental illness: a systematic literature review.

Authors:  Leopoldo J Cabassa; Jerel M Ezell; Roberto Lewis-Fernández
Journal:  Psychiatr Serv       Date:  2010-08       Impact factor: 3.084

4.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

Review 5.  Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review.

Authors:  Nick Verhaeghe; Jan De Maeseneer; Lea Maes; Cornelis Van Heeringen; Lieven Annemans
Journal:  Int J Behav Nutr Phys Act       Date:  2011-04-11       Impact factor: 6.457

Review 6.  Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

7.  Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

Authors:  Ren-Rong Wu; Jing-Ping Zhao; Zhe-Ning Liu; Jin-Guo Zhai; Xiao-Feng Guo; Wen-Bing Guo; Jing-Song Tang
Journal:  Psychopharmacology (Berl)       Date:  2006-04-07       Impact factor: 4.530

8.  Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.

Authors:  H G Shertzer; E L Kendig; H A Nasrallah; E Johansson; M B Genter
Journal:  Int J Obes (Lond)       Date:  2010-01-12       Impact factor: 5.095

9.  Binge eating symptomatology in overweight and obese patients with schizophrenia: a case control study.

Authors:  Yasser Khazaal; Emmanuelle Frésard; François Borgeat; Daniele Zullino
Journal:  Ann Gen Psychiatry       Date:  2006-09-12       Impact factor: 3.455

10.  Low prevalence of lipid metabolism abnormalities in APOE ε2-genotype and male patients 60 years or older with schizophrenia.

Authors:  Chunxia Ban; Qunying Zhang; Jie Feng; Huijuan Li; Qi Qiu; Yuan Tian; Xia Li
Journal:  BMC Psychiatry       Date:  2017-12-12       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.